Global Community

Our community narratives are driven by numbers and valuation.

Author Program NEW

Community Investing Ideas

Global Weekly Picks

META logo
Meta Platforms

The $135 Billion Bet That Should Make Every Shareholder Nervous

Meta still throws off huge cash from Facebook, Instagram, and WhatsApp, but its founder is pouring massive resources into building next‑generation AI and other long-shot bets that may never pay off. With regulators around the world pushing harder on child safety, advertising practices, and data use, the real question is whether this cash machine can stay steady while the company chases its newest obsession.
View narrative
US$586
FV
4.6% undervalued intrinsic discount
8.89%
Revenue growth p.a.
6.1k
users have viewed this narrative
33users have liked this narrative
3users have commented on this narrative
45users have followed this narrative
ALV logo
Alvopetro Energy

Alvopetro Energy - Good Dividend but limited upside potential at price around $10

BASE — production ramps as guided, gas price normalizes off the contracted peak. The is the future estimate in 3 years.Read more

View narrative
CA$10.15
3.9% undervalued intrinsic discount
Fair Value
Revenue
9.2% p.a.
Profit Margin
45%
Future PE
9.5x
Price in 2029
CA$12.24
COLO B logo
Coloplast

Coloplast: A Rare Entry Point in Quality Healthcare

Republishing Note This article was originally published on my Substack on the 2nd of July 2026 and is republished here for wider distribution. Note: This report has been corrected since publication.Read more

View narrative
DKK 737
37.2% undervalued intrinsic discount
Fair Value
ref Valuation section
CELH logo
Celsius Holdings

Celsius Holdings: Undervalued Growth Opportunity Or Trap?

Celsius is growing again on paper, but the original Celsius brand is shrinking while its biggest partner also controls most of its sales and distribution. See why some investors think the recent slowdown is a temporary channel shake‑up—and why others worry it signals deeper demand and leadership problems.Read more

View narrative
US$41
14.6% undervalued intrinsic discount
Fair Value
The fine print at the bottom of the graphic reads: > **Method.** Each year's EPS is multiplied by a fixed bear, base, and bull P/E of 18.0x, 28.0x, and 35.0x. The scenario mean is the simple average of the three outcomes, which assigns equal weight to each and is not a probability-weighted expected value. Fair value of $43.20 is the FY2026E scenario mean, undiscounted. Return convention: CAGR is compounded: $(mean \div spot)^{\frac{1}{years}} - 1$. The source sheet labeled a column CAGR that in fact divided total return by the number of years, which overstates the annualized figure in every year beyond the first (FY2029E: 43.4% simple versus 28.6% compounded). EPS basis: The FY2026E–FY2029E EPS path used here differs from the earnings model in Exhibit 1; refer to the text before publication. Neither path deducts preferred dividends on the Series A and Series B convertible preferred stock. Not investment advice. No recommendation is expressed or implied. Also: The fine print at the bottom of Exhibit 1 reads: > **Basis.** FY2022A–FY2025A net revenue, cost of revenue and gross profit are per Celsius Holdings Form 10-K filings. Operating expense, operating income and net income for those years are restated to exclude non-operating items and do not tie to the filings; see model workbook. FY2026E–FY2031E: Net revenue expressed as stated growth; gross profit off stated margin; operating expense off stated growth. All sub-totals, growth rates and ratios shown here are recomputed from the table rows rather than carried forward. **Model convention.** Net income represents income before taxes and before dividends on the Series A and Series B convertible preferred stock; earnings per share is calculated on the same basis as the forecast years. Exit multiples of 18.0x, 28.0x and 35.0x are applied uniformly across all forecast years and are not derived from a discounted cash flow method; implied market capitalizations correspond directly to target prices. No price target or recommendation is expressed or implied. Then based off of my multiple models I took the average price for each year to find the CAGR and the estimated fair value.
MEDP logo
Medpace Holdings

Why Medpace Outperforms Competitors in the Mid-Sized Biotech Niche

Medpace Holdings is a clinical research organization, or CRO. The simplest way to understand a CRO is to think of it as a general contractor for clinical trials.Read more

View narrative
US$536
15.7% overvalued intrinsic discount
Fair Value
Revenue
4.21% p.a.
Profit Margin
17.67%
Future PE
35.21x
Price in 2031
US$787.09